Pharmacogenetics in the management of breast cancer

Sacha J. Howell

doi:10.1007/978-90-481-8618-1_4

Pharmacogenetics in the management of breast cancer

Research output: Chapter in Book/Conference proceeding › Chapter

Abstract

The estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2) represent key pharmacogenomic targets for effective therapies in breast oncology. Furthermore, recent advances in genomic approaches to clarify prognosis have refined the use of cytotoxic chemotherapy, although a great many women still receive unnecessary and often ineffective treatment. Pharmacogenetic factors involved in the metabolism of some of these drugs, and in particular the influence of CYP2D6 polymorphisms in the metabolism of tamoxifen, have begun to change clinical practice. The routine genotyping of drug metabolic pathways may well become another standard measure in breast oncology in the near future. © 2010 Springer Science+Business Media B.V.

Original language	English
Title of host publication	Pharmacogenetics: Making Cancer Treatment Safer and More Effective\|Pharmacogenetics: Mak. Cancer Treatm. Safer and More Effective
Publisher	Springer Nature
Pages	45-59
Number of pages	14
Edition	1
DOIs	https://doi.org/10.1007/978-90-481-8618-1_4
Publication status	Published - 2010

Keywords

CYP2D6
Estrogen receptor
Herceptin
Oncotype DX
Tamoxifen

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/978-90-481-8618-1_4

Cite this

@inbook{639b14a34871413abdae34ee424b84c4,

title = "Pharmacogenetics in the management of breast cancer",

abstract = "The estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2) represent key pharmacogenomic targets for effective therapies in breast oncology. Furthermore, recent advances in genomic approaches to clarify prognosis have refined the use of cytotoxic chemotherapy, although a great many women still receive unnecessary and often ineffective treatment. Pharmacogenetic factors involved in the metabolism of some of these drugs, and in particular the influence of CYP2D6 polymorphisms in the metabolism of tamoxifen, have begun to change clinical practice. The routine genotyping of drug metabolic pathways may well become another standard measure in breast oncology in the near future. {\textcopyright} 2010 Springer Science+Business Media B.V.",

keywords = "CYP2D6, Estrogen receptor, Herceptin, Oncotype DX, Tamoxifen",

author = "Howell, {Sacha J.}",

year = "2010",

doi = "10.1007/978-90-481-8618-1_4",

language = "English",

pages = "45--59",

booktitle = "Pharmacogenetics: Making Cancer Treatment Safer and More Effective|Pharmacogenetics: Mak. Cancer Treatm. Safer and More Effective",

publisher = "Springer Nature",

address = "United States",

edition = "1",

}

TY - CHAP

T1 - Pharmacogenetics in the management of breast cancer

AU - Howell, Sacha J.

PY - 2010

Y1 - 2010

N2 - The estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2) represent key pharmacogenomic targets for effective therapies in breast oncology. Furthermore, recent advances in genomic approaches to clarify prognosis have refined the use of cytotoxic chemotherapy, although a great many women still receive unnecessary and often ineffective treatment. Pharmacogenetic factors involved in the metabolism of some of these drugs, and in particular the influence of CYP2D6 polymorphisms in the metabolism of tamoxifen, have begun to change clinical practice. The routine genotyping of drug metabolic pathways may well become another standard measure in breast oncology in the near future. © 2010 Springer Science+Business Media B.V.

AB - The estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2) represent key pharmacogenomic targets for effective therapies in breast oncology. Furthermore, recent advances in genomic approaches to clarify prognosis have refined the use of cytotoxic chemotherapy, although a great many women still receive unnecessary and often ineffective treatment. Pharmacogenetic factors involved in the metabolism of some of these drugs, and in particular the influence of CYP2D6 polymorphisms in the metabolism of tamoxifen, have begun to change clinical practice. The routine genotyping of drug metabolic pathways may well become another standard measure in breast oncology in the near future. © 2010 Springer Science+Business Media B.V.

KW - CYP2D6

KW - Estrogen receptor

KW - Herceptin

KW - Oncotype DX

KW - Tamoxifen

U2 - 10.1007/978-90-481-8618-1_4

DO - 10.1007/978-90-481-8618-1_4

M3 - Chapter

SP - 45

EP - 59

BT - Pharmacogenetics: Making Cancer Treatment Safer and More Effective|Pharmacogenetics: Mak. Cancer Treatm. Safer and More Effective

PB - Springer Nature

ER -

Pharmacogenetics in the management of breast cancer

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this